JP2000136124A - Skin lotion - Google Patents

Skin lotion

Info

Publication number
JP2000136124A
JP2000136124A JP30980998A JP30980998A JP2000136124A JP 2000136124 A JP2000136124 A JP 2000136124A JP 30980998 A JP30980998 A JP 30980998A JP 30980998 A JP30980998 A JP 30980998A JP 2000136124 A JP2000136124 A JP 2000136124A
Authority
JP
Grant status
Application
Patent type
Prior art keywords
skin
scientific name
extract
oligopeptide
chlorella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP30980998A
Other languages
Japanese (ja)
Inventor
Mikio Miyahara
Kazutoshi Sakamoto
Takeshi Shigematsu
Masako Tsutsumi
雅子 堤
幹夫 宮原
剛 重松
和俊 阪本
Original Assignee
Pias Arise Kk
ピアス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Abstract

PROBLEM TO BE SOLVED: To obtain a skin lotion capable of keeping the skin elastic, fresh and young by controlling a skin differentiation and a skin proliferation by inhibiting an elastase activity. SOLUTION: This skin lotion comprises either or both of (1) a component comprising an oligopeptide having an amino acid sequence consisting of Val-Gly- Val-Ala-Pro-Gly, a polypeptide, a protein or an extract containing the oligopeptide and (2) a component comprising one or more kinds of extracts selected from the extract of Chlorella (Chlorella), Ascophyllum (scientific name: Ascophyllum Nodosum), Silybum marianum Gaertn (scientific name: Silybum marianum (L) Gaertn) or Centella asiatica (scientific name: Centella asiatica (L) Urb).

Description

【発明の詳細な説明】 DETAILED DESCRIPTION OF THE INVENTION

【0001】 [0001]

【発明の属する技術分野】本発明は、皮膚外用剤に関し、特に、弾力性のあるみずみずしい皮膚をつくる皮膚外用剤に関する。 The present invention relates to relates to a skin external agent, in particular, it relates to skin external agent to make the fresh skin resilient.

【0002】 [0002]

【従来の技術】近年、皮膚の老化に関する研究が急速に進み、組織レベル、細胞レベル又は分子レベルでの皮膚の老化の過程が明かになったきた。 In recent years, rapid progress studies on skin aging, tissue level, north course of aging of the skin at the cellular level or molecular level becomes apparent. 即ち、皮膚の老化は遺伝子レベルでの避けることのできない現象である一方、紫外線等の太陽光の影響や乾燥、酸化などの環境要因によっても促進されることがわかってきた。 That is, aging of the skin whereas a phenomenon that can not be avoided at the genetic level, solar effects and drying such as ultraviolet rays, has been found to be facilitated by environmental factors such as oxidation.

【0003】具体的には、酵素やラジカルの作用によって組織が分解、変性されることにより皮膚が弾力性を失い、老化が促進される。 [0003] More specifically, the tissue by the action of the enzyme and radicals decomposed skin by being modified loses elasticity, aging is accelerated.

【0004】例えば、ケラチノサイトの正常な増殖や分化を維持することにより、適度な水分を角層内に保留でき、小皺、落屑、乾燥を防いでみずみずしい皮膚を保つことができることが知られている。 [0004] For example, by maintaining the normal growth and differentiation of keratinocytes, it can hold an appropriate moisture corner layer, fine lines, scaling, it is known that it is possible to maintain the fresh skin to prevent drying.

【0005】また、真皮に存在するエラスチンは、酵素エラスターゼやラジカルによって分解、変性され、このエラスチンが分解、変成されることにより皮膚が弾力性を失い、老化が促進されることが知られている。 Moreover, elastin present in the dermis, the decomposition by the enzyme elastase or radicals, are modified, skin by the elastin degradation is modified loses elasticity, it is known that aging is promoted .

【0006】更に、本発明者らは、皮膚の老化現象について鋭意研究を重ねた結果、前記エラスチンは、真皮のみならず表皮にも存在し、この表皮のエラスチンがエラスターゼやラジカル等によって分解され、これが表皮細胞の正常な角化に影響を与え、ハリ、小皺、クスミ、乾燥等、皮膚の老化の原因となること、即ち、エラスターゼの活性を阻害することが、真皮のエラスチンの老化を抑制するのみならず、表皮のエラスチンをも正常に保ち、水分保持能に富んだ弾力性のある角質層を作ることを見い出した。 Furthermore, the present inventors have found, after extensive research on aging of the skin, the elastin, also present in the epidermis as well dermis only, elastin of the skin is degraded by elastase or radicals such as, This affects the normal keratinocytes of epidermal cells, needles, wrinkles, dullness, drying and the like, can cause skin aging, i.e., to inhibit the activity of elastase, inhibit aging of dermal elastin not only, also maintained normally elastin of the skin, it has been found to make the stratum corneum with a rich resilient to moisture-retaining ability.

【0007】 [0007]

【発明が解決しようとする課題】そこで、本発明は上記知見に基づいて、皮膚の分化と増殖の制御及びエラスターゼ活性の抑制効果のいずれか又は双方により弾力性のあるみずみずしい皮膚を保つことができる皮膚外用剤を提供することを課題とする。 [SUMMARY OF THE INVENTION Therefore, the present invention is based on the above findings, it is possible to maintain the fresh skin resilient by either or both of the inhibitory effect of the control and elastase activity proliferation and differentiation of the skin to provide a skin external agent to issue.

【0008】 [0008]

【課題を解決するための手段】本発明は上記課題を解決するためになされたもので、本発明者は、アミノ酸配列Val Gly Val Ala Pro Glyからなるオリゴペプチド又は該オリゴペプチドを含むポリペプチド、タンパク質若しくはエキスがケラチノサイトの正常な分化と増殖を維持することを見い出し、該成分を配合してなることを特徴とする本発明を完成した。 SUMMARY OF THE INVENTION The present invention has been made to solve the above problems, the present inventors have polypeptide comprising an oligopeptide or the oligopeptide consisting of the amino acid sequence Val Gly Val Ala Pro Gly, It found that the protein or the extract to maintain growth and normal differentiation of keratinocytes, and completed the present invention characterized by comprising blending the components.

【0009】上記アミノ酸配列を有するオリゴペプチド又は該オリゴペプチドを含むタンパク質等を配合してなる皮膚外用剤によれば、適度な水分を角層内に保留できる結果、弾力性のあるみずみずしい皮膚を保つことができる。 According to external skin preparation by blending the protein or the like comprising an oligopeptide or the oligopeptide having the amino acid sequence, results that can hold an appropriate moisture corner layer, keeping the fresh skin resilient be able to.

【0010】また、本発明者は、請求項2記載のクロレラ(Chlorella属)、アスコフィラム(学名: Further, the present inventor has Chlorella according to claim 2, wherein (Chlorella sp), Ascophyllum (scientific name:
Ascophyllum Nodosum)、オオアザミ(学名: SilybummarianumL.)、 Ascophyllum Nodosum), milk thistle (scientific name: SilybummarianumL),.
雪積草(学名:Cetella asiatica Yukisekikusa (scientific name: Cetella asiatica
(L)Urb)のエキスが、エラスターゼ活性を阻害することを見い出し、該エキスから選ばれた一種又は二種以上を配合してなることを特徴とする本発明を完成した。 Extract (L) Urb) are found to inhibit elastase activity, and completed the present invention characterized by comprising blending one or more kinds selected from the extract.

【0011】本発明の前記エキスのエラスターゼ活性阻害効果に関するエラスターゼ活性阻害評価について、試験方法及びその試験結果を以下に説明する。 [0011] The elastase activity inhibition Evaluation of elastase activity inhibitory effect of the extract of the present invention, illustrating a test method and the test results are described below.

【0012】 試験方法前記エラスターゼ活性阻害評価は、Bieth J. [0012] The test method the elastase activity inhibition evaluation, Bieth J.
(参考文献The synthesis and an (Ref. The synthesis and an
alytical use of a highly alytical use of a highly
sensitive and convenient sensitive and convenient
substrate of elastase. substrate of elastase. Bio Bio
chem. chem. Med. Med. 1974;11)らの方法に基づいて実施した。 1974; 11) was performed on the basis of these methods.

【0013】まず、至適濃度の各評価試料をPBSに加え、最終100μlに調整した。 [0013] First, adding each evaluation sample optimal concentration in PBS, and adjusted to a final 100 [mu] l. 各試料溶液100μl Each sample solution 100μl
にエラスチンの合成基質であるSuccinyl−L− Succinyl-L- is a synthetic substrate of elastin
(alanyl)3−Paranitioanilid (Alanyl) 3-Paranitioanilid
eを50mM Tris−HCL(pH7.8)の条件で等量加え、18時間インキュベートした。 Adding an equal volume of e in terms of 50mM Tris-HCL (pH7.8), and incubated for 18 hours.

【0014】その後、410nmの吸光度の変化により、エラスターゼ活性阻害効果を測定した。 [0014] After that, by a change in the 410nm absorbance was measured elastase activity inhibitory effect. 尚、コントロールには、試料無添加の溶液を用いた。 Incidentally, the control, was used a solution of the sample without additives.

【0015】 試験結果上記試験の結果を表1に示す。 [0015] Table 1 shows the results of test results the test.

【表1】 [Table 1]

【0016】上記クロレラ等のエキスを配合してなる皮膚外用剤によれば、表皮及び真皮のエラスチンを正常に保つことができる結果、弾力性のあるみずみずしい皮膚を保つことができる。 According to the skin external preparation obtained by blending the extract such as the chlorella, results that can be kept normal epidermis and dermis of elastin, it can be kept fresh skin resilient.

【0017】従って、上記請求項2記載の皮膚外用剤は、エラスターゼ活性阻害剤であることを好適とする。 [0017] Thus, the skin external preparation of the second aspect, and preferably that the elastase activity inhibitor.

【0018】また、請求項3の如く、上記アミノ酸配列Val Gly Val AlaPro Glyからなるオリゴペプチド又は該オリゴペプチドを含むタンパク質等及び上記クロレラのエキス等を併用配合してなれば、皮膚の分化と増殖の制御及びエラスターゼ活性の抑制効果が相乗的に発揮され、一層弾力性のあるみずみずしい皮膚を保つことができる。 Further, as in claim 3, if in combination blending the amino acid sequence Val Gly Val AlaPro proteins, etc. containing oligopeptide or the oligopeptide consisting Gly and the chlorella extract, etc., and differentiation of skin proliferation inhibiting effect of the control and elastase activity is synergistically exerted, it is possible to maintain the fresh skin more resilient.

【0019】更に、上記本発明の皮膚外用剤は、抗老化剤又は角化改善用外用剤であることを好適とする。 Furthermore, the skin external preparation of the present invention is suitable to be an anti-aging agent or keratinization improving agent for external use.

【0020】以下、本発明の構成について詳述する。 [0020] In the following, it will be described in detail the structure of the present invention.

【0021】本発明の皮膚外用剤は、アミノ酸配列Va [0021] The skin external preparation of the present invention, the amino acid sequence Va
l Gly Val Ala Pro Glyからなるオリゴペプチドを構成成分として配合したもの、又は前記オリゴペプチドを含むポリペプチド、タンパク質若しくはエキスを構成成分として配合したものである。 Those containing a combination of an oligopeptide consisting of l Gly Val Ala Pro Gly as a component, or a polypeptide comprising said oligopeptide is obtained by mixing the protein or extract as a component. 尚、 still,
前記オリゴペプチドは、塩酸塩や酢酸塩等の塩として配合されてなってもよく、また、前記アミノ酸配列を有するものであれば、その起源は問わない。 The oligopeptide may be made formulated as salts such as hydrochlorides or acetates, and as long as it has the amino acid sequence, its origin is not particularly limited.

【0022】また、請求項2記載の発明において用いられるクロレラ(Chlorella属)、アスコフィラム(学名:Ascophyllum Nodosu Further, chlorella used in the invention of claim 2 wherein (Chlorella sp), Ascophyllum (scientific name: Ascophyllum Nodosu
m)、オオアザミ(学名: Silybummaria m), milk thistle (scientific name: Silybummaria
numL. numL. )、雪積草(学名:Cetella asi ), Yukisekikusa (scientific name: Cetella asi
atica(L)Urb)の植物エキスは、その葉、 Plant extracts of atica (L) Urb), the leaves,
茎、花、樹皮、種子、果実又は植物前草を抽出溶媒とともに浸漬又は加熱貫流した後、ろ過し、濃縮して得られる。 Stems, flowers, bark, seeds, after immersion or heated flow with extraction solvent fruit or vegetable before grasses, filtered and the resulting concentrated.

【0023】前記抽出溶媒は、通常抽出に用いられる溶媒であれば特に限定されず、メタノール、エタノール等のアルコール類、含水アルコール類、アセトン、酢酸エチルエステル等の有機溶媒を単独あるいは組み合わせて用いることができる。 [0023] The extraction solvent is not particularly limited as long as the solvent usually used for extraction, alcohols such as methanol and ethanol, water-containing alcohols, acetone, be used alone or in combination with organic solvents such as ethyl acetate ester can.

【0024】また、本発明における前記エキスの配合量は、皮膚外用剤全量中、乾燥物0.0005〜50.0 [0024] The amount of the extract in the present invention, in the total amount of the skin treatment composition, dry matter from 0.0005 to 50.0
重量%、好ましくは0.001〜10.0重量%である。 Wt%, preferably from 0.001 to 10.0 wt%. 前記配合量が0.0005重量%未満であると、本発明でいう効果が充分に発揮されず、50.0重量%を越えると、製剤化が難しいので好ましくなく、また、1 When the amount is less than 0.0005 wt%, the effect in the present invention is not sufficiently exhibited, and when it exceeds 50.0 wt%, it is not preferable because it is difficult formulation, also 1
0.0重量%以上配合しても大きな効果の向上はみられないからである。 Be added 0.0 wt% or more improvement in the large effect is because not seen.

【0025】更に、本発明の皮膚外用剤には、上記必須の成分以外に通常化粧品や医薬品等の皮膚外用剤に用いられる成分、例えば、美白剤、保湿剤、酸化防止剤、油性成分、紫外線吸収剤、界面活性剤、増粘剤、アルコール類、粉末成分、色材、水性成分、水、各種栄養剤等を適宜配合することができる。 Furthermore, the skin external preparation of the present invention, the essential components used in ordinary cosmetics and skin external preparations such as medicines in addition to components, for example, whitening agents, humectants, antioxidants, oil components, ultraviolet absorbents, surfactants, thickeners, alcohols, powder components, coloring material can be formulated aqueous component, water, various nutrients, or the like as appropriate.

【0026】また、本発明の皮膚外用剤とは、例えば、 [0026] In addition, the skin external preparation of the present invention, for example,
軟膏、クリーム、乳液、ローション、パック、浴用剤等、従来より皮膚外用剤として用いられているものであればいずれでもよく、剤型は特に問わない。 Ointments, creams, milks, lotions, packs, bath agents, etc., may be any as long as it is conventionally used as a skin external preparation, the dosage form is not particularly limited.

【0027】 [0027]

【実施例】次に、本発明の実施例について、種々の剤型の配合例を説明する。 EXAMPLES Next, EXAMPLES of the present invention, illustrating the formulation examples of various dosage forms. 尚、本発明はこれに限定されるものではない。 The present invention is not limited thereto. また、各実施例のオリゴペプチドはアミノ酸配列Val Gly Val Ala Pro Gl Further, an oligopeptide of the examples the amino acid sequence Val Gly Val Ala Pro Gl
yからなるオリゴペプチドを示す。 It shows an oligopeptide consisting of y.

【0028】 実施例1本実施例では、下記に示す処方に基づいてクリームを作成した。 [0028] EXAMPLE 1 In this example, have created a cream based on the formulation shown below. 尚、各成分の数値は重量%を示す。 The numerical values ​​of each component was measured by weight. セタノール 2.0 親油型モノステアリン酸グリセリン 3.5 流動パラフィン 10.0 イソノナン酸2−エチルヘキシル 10.0 モノステアリン酸ソルビタン 4.5 メチルポリシロキサン 1.0 N−アシル−L−グルタミン酸ナトリウム 0.5 1,3−ブチレングリコール 5.0 濃グリセリン 10.0 パラベン 0.2 オリゴペプチドの塩酸塩 0.5 クロレラエキス 0.2 アスコフィラムエキス 0.5 オオアザミエキス 0.1 雪積草エキス 0.3 精製水 残量 Cetanol 2.0 lipophilic glycerin monostearate 3.5 Liquid paraffin 10.0 isononanoate, 2-ethylhexyl 10.0 Sorbitan monostearate 4.5 methylpolysiloxane 1.0 N-acyl -L- glutamate sodium 0. 5 1,3-butylene glycol 5.0 hydrochloride 0.5 of concentrated glycerin 10.0 paraben 0.2 oligopeptide chlorella extract 0.2 ascorbyl Fi ram extract 0.5 giant thistle extract 0.1 Yukisekikusa extract 0. 3 purified water Balance

【0029】 実施例2本実施例では、下記に示す処方に基づいてエッセンスを作成した。 [0029] Example 2 In this Example, were prepared essence based on the formulation shown below. 尚、各成分の数値は重量%を示す。 The numerical values ​​of each component was measured by weight. 1,3−ブチレングリコール 5.0 濃グリセリン 10.0 クエン酸 0.02 クエン酸ナトリウム 0.1 ヒアルロン酸ナトリウム 0.2 パラベン 0.2 オリゴペプチドの酢酸塩 0.2 クロレラエキス 2.0 アスコフィラムエキス 2.0 オオアザミエキス 0.2 雪積草エキス 0.2 精製水 残量 Acetate 1,3-butylene glycol 5.0 Concentrated glycerin 10.0 Citric acid 0.02 Sodium citrate 0.1 Sodium hyaluronate 0.2 paraben 0.2 oligopeptide 0.2 chlorella extract 2.0 Asukofi rum 2.0 giant thistle extract 0.2 Yukisekikusa extract 0.2 purified water Balance

【0030】 実施例3本実施例では、下記に示す処方に基づいてローションを作成した。 [0030] EXAMPLE 3 In this example, have created a lotion based on the formulation shown below. 尚、各成分の数値は重量%を示す。 The numerical values ​​of each component was measured by weight. エタノール 5.0 ポリオキシエチレン硬化ヒマシ油 0.3 濃グリセリン 3.0 1,3−ブチレングリコール 5.0 クエン酸 0.02 クエン酸ナトリウム 0.1 オリゴペプチドの塩酸塩 0.1 クロレラエキス 1.0 アスコフィラムエキス 1.0 オオアザミエキス 0.1 雪積草エキス 0.1 精製水 残量 Ethanol 5.0 hydrochloride polyoxyethylene hydrogenated castor oil 0.3 Concentrated glycerin 3.0 1,3-butylene glycol 5.0 Citric acid 0.02 Sodium citrate 0.1 oligopeptides 0.1 chlorella extract 1. 0 ascorbyl Fi rum extract 1.0 giant thistle extract 0.1 Yukisekikusa extract 0.1 purified water Balance

【0031】 [0031]

【発明の効果】以上のように、請求項1記載の皮膚外用剤によれば、特定のアミノ酸配列を持つペプチドを配合してなることにより、適度な水分を角層内に保留して、 As is evident from the foregoing description, according to the skin external preparation according to claim 1, by by blending the peptide with specific amino acid sequences, pending the proper moisture corner layer,
弾力性のあるみずみずしい皮膚を保ち、結果、たるみのない若々しい皮膚をつくることができる。 Keep the fresh skin that is resilient, a result, it is possible to create a youthful skin without sagging.

【0032】また、請求項2記載の皮膚外用剤によれば、特定のエキスを配合してなることにより、エラスターゼ活性を阻害して、表皮及び真皮のエラスチンを正常に保ち、弾力性のあるみずみずしい皮膚を保つことができる結果、たるみのない若々しい皮膚をつくることができる。 Further, according to claim 2, wherein the skin external preparation, by obtained by blending a specific extract, inhibit elastase activity, normally epidermis and dermis elastin maintained, fresh resilient a result that it is possible to keep the skin, it is possible to create a youthful skin without sagging.

【0033】従って、上記請求項2記載の皮膚外用剤は、エラスターゼ活性阻害剤であることを好適とする。 [0033] Thus, the skin external preparation of the second aspect, and preferably that the elastase activity inhibitor.

【0034】また、請求項1記載の成分と請求項2記載の成分とを併用配合してなれば、皮膚の分化と増殖の制御及びエラスターゼ活性の抑制の相乗効果によって、より一層若々しい皮膚をつくることができる。 Further, if used in combination blending the ingredients of claim 2 wherein the component of claim 1, wherein, by the synergistic effect of the suppression of the control and elastase activity proliferation and differentiation of the skin, more youthful skin it can make.

【0035】従って、上記本発明の皮膚外用剤は、抗老化剤又は角化改善用外用剤であることを好適とする。 [0035] Thus, the skin external preparation of the present invention is suitable to be an anti-aging agent or keratinization improving agent for external use.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl. 7識別記号 FI テーマコート゛(参考) A61P 17/12 A61K 31/00 617G 17/00 617 A61K 35/78 35/78 C 35/80 35/80 A 38/00 37/02 (72)発明者 重松 剛 大阪府大阪市北区豊崎3丁目19番3号 ピ アス株式会社内 (72)発明者 堤 雅子 大阪府大阪市北区豊崎3丁目19番3号 ピ アス株式会社内 Fターム(参考) 4C083 AA111 AC022 AC072 AC102 AC122 AC242 AC302 AC352 AC422 AC432 AC442 AC482 AC662 AD152 AD332 AD411 AD412 CC02 CC04 CC05 DD27 DD31 EE06 EE07 EE12 EE13 4C084 AA02 BA01 BA02 BA17 DC41 MA22 MA28 MA63 ZA892 ZC202 ZC522 4C088 AA16 AB26 AB99 AC01 AC03 AC04 AC05 AC06 AC15 BA08 BA10 BA16 MA07 MA63 NA14 ZA89 ZC20 ZC52 ────────────────────────────────────────────────── ─── of the front page continued (51) Int.Cl. 7 identification mark FI theme Court Bu (reference) A61P 17/12 A61K 31/00 617G 17/00 617 A61K 35/78 35/78 C 35/80 35/80 a 38/00 37/02 (72) inventor Shigematsu Tsuyoshi Osaka-shi, Osaka, Kita-ku Toyosaki 3-chome 19th No. 3 pin Us within Co., Ltd. (72) inventor Masako Tsutsumi Osaka-shi, Osaka, Kita-ku Toyosaki 3-chome # 19 No. 3 pin Us, Inc. in the F-term (reference) 4C083 AA111 AC022 AC072 AC102 AC122 AC242 AC302 AC352 AC422 AC432 AC442 AC482 AC662 AD152 AD332 AD411 AD412 CC02 CC04 CC05 DD27 DD31 EE06 EE07 EE12 EE13 4C084 AA02 BA01 BA02 BA17 DC41 MA22 MA28 MA63 ZA892 ZC202 ZC522 4C088 AA16 AB26 AB99 AC01 AC03 AC04 AC05 AC06 AC15 BA08 BA10 BA16 MA07 MA63 NA14 ZA89 ZC20 ZC52

Claims (6)

    【特許請求の範囲】 [The claims]
  1. 【請求項1】 アミノ酸配列Val Gly Val [Claim 1] amino acid sequence Val Gly Val
    Ala Pro Glyからなるオリゴペプチド又は該オリゴペプチドを含むポリペプチド、タンパク質若しくはエキスを配合してなることを特徴とする皮膚外用剤。 Ala Pro skin external agent characterized in that by blending a polypeptide, protein or extracts containing oligopeptide or the oligopeptide consists of Gly.
  2. 【請求項2】 クロレラ(Chlorella属)、アスコフィラム(学名:Ascophyllum Nod 2. The method of claim 1] Chlorella (Chlorella spp.), Ascophyllum (scientific name: Ascophyllum Nod
    osum)、オオアザミ(学名: Silybumma osum), milk thistle (scientific name: Silybumma
    rianumL. rianumL. )、雪積草(学名:Cetella ), Yukisekikusa (scientific name: Cetella
    asiatica(L)Urb)のエキスから選ばれた一種又は二種以上を配合してなることを特徴とする皮膚外用剤。 asiatica (L) skin external agent characterized in that by blending one or two or more selected from extract Urb).
  3. 【請求項3】 エラスターゼ活性阻害剤である請求項2 A wherein elastase activity inhibitor according to claim 2
    記載の皮膚外用剤。 Skin external preparation as described.
  4. 【請求項4】 アミノ酸配列Val Gly Val 4. The amino acid sequence Val Gly Val
    Ala Pro Glyからなるオリゴペプチド又は該オリゴペプチドを含むポリペプチド、タンパク質若しくはエキスと、クロレラ(Chlorella属)、アスコフィラム(学名:Ascophyllum Nodo Polypeptide comprising an oligopeptide or the oligopeptide consists ala Pro Gly, and proteins or extract, chlorella (Chlorella sp), Ascophyllum (scientific name: Ascophyllum Nodo
    sum)、オオアザミ(学名: Silybummar sum), milk thistle (scientific name: Silybummar
    ianumL. ianumL. )、雪積草(学名:Cetella a ), Yukisekikusa (scientific name: Cetella a
    siatica(L)Urb)のエキスから選ばれた一種又は二種以上とを配合してなることを特徴とする皮膚外用剤。 siatica (L) skin external agent characterized in that by blending a selected one or two or more from the extract Urb).
  5. 【請求項5】 抗老化剤である請求項1、2又は4のいずれかに記載の皮膚外用剤。 5. A skin external preparation according to any one of claims 1, 2 or 4 which is an anti-aging agent.
  6. 【請求項6】 角化改善用外用剤である請求項1、2又は4のいずれかに記載の皮膚外用剤。 6. The external preparation for skin according to any one of claims 1, 2 or 4 is keratinization improving agent for external use.
JP30980998A 1998-10-30 1998-10-30 Skin lotion Pending JP2000136124A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP30980998A JP2000136124A (en) 1998-10-30 1998-10-30 Skin lotion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP30980998A JP2000136124A (en) 1998-10-30 1998-10-30 Skin lotion

Publications (1)

Publication Number Publication Date
JP2000136124A true true JP2000136124A (en) 2000-05-16

Family

ID=17997517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP30980998A Pending JP2000136124A (en) 1998-10-30 1998-10-30 Skin lotion

Country Status (1)

Country Link
JP (1) JP2000136124A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002308791A (en) * 2001-04-11 2002-10-23 Pias Arise Kk Ceramidase activity inhibitor, skin care preparation containing the activity inhibitor, cosmetic, and quasi-drug
WO2003000222A2 (en) * 2001-06-22 2003-01-03 Gecomwert Anstalt Cosmetic preparation with anti-wrinkle action
WO2003099248A1 (en) * 2002-05-24 2003-12-04 Johnson & Johnson Consumer Companies, Inc. Composition containing a peptide and a pigment and the use thereof in darkening the skin
US6797697B2 (en) * 2001-05-21 2004-09-28 Johnson & Johnson Consumer Companies, Inc. Composition containing a peptide and a pigment and the use thereof in darkening the skin
FR2854897A1 (en) * 2003-05-12 2004-11-19 Sederma Sa Cosmetic or dermopharmaceutical compositions to reduce the signs of skin aging.
WO2006053688A1 (en) * 2004-11-17 2006-05-26 Henkel Kommanditgesellschaft Auf Aktien Cosmetic and dermatological preparations for the treatment of mature skin
US7381707B2 (en) 2005-06-30 2008-06-03 Johnson & Johnson Consumer Companies, Inc. Treatment of dry eye
FR2957252A1 (en) * 2010-03-09 2011-09-16 Lvmh Rech cosmetic Composition
JP2013035808A (en) * 2011-08-10 2013-02-21 Rohto Pharmaceutical Co Ltd Ltbp-4 production promotor
JP2014509631A (en) * 2011-04-01 2014-04-21 ロレアル To reduce or delay the signs of skin aging, the use of zingerone or derivatives thereof

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002308791A (en) * 2001-04-11 2002-10-23 Pias Arise Kk Ceramidase activity inhibitor, skin care preparation containing the activity inhibitor, cosmetic, and quasi-drug
US6797697B2 (en) * 2001-05-21 2004-09-28 Johnson & Johnson Consumer Companies, Inc. Composition containing a peptide and a pigment and the use thereof in darkening the skin
WO2003000222A2 (en) * 2001-06-22 2003-01-03 Gecomwert Anstalt Cosmetic preparation with anti-wrinkle action
WO2003000222A3 (en) * 2001-06-22 2004-04-29 Gecomwert Anstalt Cosmetic preparation with anti-wrinkle action
WO2003099248A1 (en) * 2002-05-24 2003-12-04 Johnson & Johnson Consumer Companies, Inc. Composition containing a peptide and a pigment and the use thereof in darkening the skin
FR2854897A1 (en) * 2003-05-12 2004-11-19 Sederma Sa Cosmetic or dermopharmaceutical compositions to reduce the signs of skin aging.
KR101231914B1 (en) * 2003-05-12 2013-02-08 쎄데르마 Cosmetic or dermopharmaceutical composition for reducing the signs of cutaneous ageing
JP2007536205A (en) * 2003-05-12 2007-12-13 セダーマ Cosmetic or dermopharmaceutical composition for the aging inhibition of skin
WO2006053688A1 (en) * 2004-11-17 2006-05-26 Henkel Kommanditgesellschaft Auf Aktien Cosmetic and dermatological preparations for the treatment of mature skin
US7381707B2 (en) 2005-06-30 2008-06-03 Johnson & Johnson Consumer Companies, Inc. Treatment of dry eye
FR2957252A1 (en) * 2010-03-09 2011-09-16 Lvmh Rech cosmetic Composition
JP2014509631A (en) * 2011-04-01 2014-04-21 ロレアル To reduce or delay the signs of skin aging, the use of zingerone or derivatives thereof
JP2013035808A (en) * 2011-08-10 2013-02-21 Rohto Pharmaceutical Co Ltd Ltbp-4 production promotor

Similar Documents

Publication Publication Date Title
US6468564B1 (en) Topical compositions containing lotus for skin treatment
US20070166267A1 (en) Anti-wrinkle composition
US7160560B2 (en) Skin-care composition
EP0727217A2 (en) Pharmaceutical composition containing god-type ellagitannin as active ingredient
WO2001094381A2 (en) Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses
JP2003201229A (en) Matrix metalloprotease activity inhibitor and ageing- resistant cosmetic
JP2003238387A (en) Skin care preparation composition for mitigating pouch and dark area under eye
JPH1072336A (en) Collagen gel contraction accelerator
US20030072732A1 (en) Cosmetic or dermatological composition comprising an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one anti-inflammatory compound
JP2000319189A (en) Elastase inhibitor, and senility-preventing skin lotion containing the same
JP2004131500A (en) Skin aging inhibitor or improver
US20030064049A1 (en) Topical anti-cancer compositions and methods of use thereof
WO2011103449A2 (en) Topical skin care formulation
US20040062731A1 (en) Topical anti-cancer compositions and methods of use thereof
JP2003300858A (en) Skin care preparation
JP2000191498A (en) Collagen production facilitative agent and preparation for external use for skin
JP2004250372A (en) Skin aging inhibitor/improver and/or rough skin inhibitor/improver kit
US20090029926A1 (en) Lys-thr dipeptides and their use
JP2000229832A (en) Skin lotion
JP2003176208A (en) Collagen gel shrinkage promoter
JP2003306438A (en) Chemokine expression inhibitor
JP2008105985A (en) Hyaluronic acid production promoter, skin care preparation for external use, bathing agent, and food and drink
JPH115975A (en) Active oxygen scavenger and use thereof
JPH10114670A (en) Composition suitable for external use
JPH07126149A (en) Cosmetic composition for beautifying and whitening

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20061109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070316